Active Filter(s):
Details:
LPCN 1154 (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. It is being evaluated for the treatment of postpartum depression.
Lead Product(s): Brexanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LPCN 1154
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
LPCN 1154 (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. It is being evaluated for the treatment of postpartum depression.
Lead Product(s): Brexanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LPCN 1154
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated in phase 2 clinical trials for the treatment of postpartum depression.
Lead Product(s): Brexanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LPCN 1154
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
LPCN 1154 is targeted to be a differentiated oral option with rapid-onset, robust efficacy, and short treatment duration as a mono or add-on therapy for patients with unresolved depression symptoms.
Lead Product(s): Brexanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LPCN 1154
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
LPCN 1154 is an oral formulation of the neuroactive steroid brexanolone for self-administration in development for the treatment of PPD. The active moiety in LPCN 1154 is a bioidentical positive allosteric modulator of y-aminobutyric acid (GABA) receptor.
Lead Product(s): Brexanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LPCN 1154
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023